A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer

Gynecol Oncol. 2011 Nov;123(2):308-13. doi: 10.1016/j.ygyno.2011.07.018. Epub 2011 Aug 19.

Abstract

Background: Previous reports have shown that the proteomic markers apolipoprotein A1, hepcidin, transferrin, inter-alpha trypsin IV internal fragment, transthyretin, connective-tissue activating protein 3 and beta-2 microglobulin may discriminate between a benign pelvic mass and ovarian cancer (OC). The aim was to determine if these serum proteomic biomarkers alone as well as in combination with age and serum CA125, could be helpful in triage of women with a pelvic mass.

Methods: We included prospectively 144 patients diagnosed with (OC), 40 with a borderline tumor and 469 with a benign tumor. Surface-enhanced laser desorption/ionization time of flight-mass spectrometry was used for analyses. The Danish Index (DK-Index) based on the proteomic data, age and CA125 was developed using logistic regression models.

Results: Multivariate logistic regression analysis demonstrated that the selected proteomic markers, CA125 and age were independent predictors of OC and the combination of these is proposed as the DK-index. A sensitivity (SN) of 99% had a specificity (SP) of 57% for DK-index and 49% for CA125. At a SN of 95%, the SP increased to 81% for DK-index compared to 68% for CA125 alone. For stage I+II the SP was 58% for DK-index and 49% for CA125. For stage III+IV the corresponding values were 94% and 86% respectively.

Conclusions: The DK-index warrants further evaluation in independent cohorts.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood*
  • CA-125 Antigen / blood
  • Female
  • Humans
  • Logistic Models
  • Middle Aged
  • Neoplasm Proteins / blood*
  • Odds Ratio
  • Ovarian Neoplasms / blood
  • Ovarian Neoplasms / diagnosis*
  • Proteomics*
  • Sensitivity and Specificity

Substances

  • Biomarkers, Tumor
  • CA-125 Antigen
  • Neoplasm Proteins